MarketPR
MDCXMedicus Pharma Regains Nasdaq Compliance After Bid Price RecoveryOct 24CPIXCumberland reports ifetroban safety data in Phase 2a trialOct 23INSWInternational Seaways subsidiary pledges VLCC tanker in $500 million credit facilityOct 23$BTCVisa In Talks To Acquire Fireblocks For $2.5 BillionOct 23BNEDBarnes & Noble Education director resigns to join PearsonOct 23REGULATORYOutKick column highlights fan fatigue over NFL flags and anthem debatesOct 23ZVIAZevia Secures $20 Million Growth Equity From GP InvestmentsOct 23MARKETSUS stocks slip pre-bell as AI spending concerns persistOct 23ENERGYFox News maps 50 Antifa groups coordinating French protest logisticsOct 23FSBWFS Bancorp appoints Matthew D. Mullet to board of directorsOct 23MDCXMedicus Pharma Regains Nasdaq Compliance After Bid Price RecoveryOct 24CPIXCumberland reports ifetroban safety data in Phase 2a trialOct 23INSWInternational Seaways subsidiary pledges VLCC tanker in $500 million credit facilityOct 23$BTCVisa In Talks To Acquire Fireblocks For $2.5 BillionOct 23BNEDBarnes & Noble Education director resigns to join PearsonOct 23REGULATORYOutKick column highlights fan fatigue over NFL flags and anthem debatesOct 23ZVIAZevia Secures $20 Million Growth Equity From GP InvestmentsOct 23MARKETSUS stocks slip pre-bell as AI spending concerns persistOct 23ENERGYFox News maps 50 Antifa groups coordinating French protest logisticsOct 23FSBWFS Bancorp appoints Matthew D. Mullet to board of directorsOct 23
NewsMacro

RBC Capital Markets downgrades Biohaven after SK Biopharma deal

RBC Capital Markets has downgraded Biohaven, pointing to the company's recent deal with SK Biopharma as the catalyst for the call. The move puts Biohaven in focus as the market weighs what the arrangement means for the near-term setup.

By Renata OstrowskiNewsroomSeptember 8, 20262 min read
Share

Key takeaways

  • RBC Capital Markets has downgraded Biohaven, citing the company's recent deal with SK Biopharma as the catalyst for the rating change.
  • RBC's view is that the SK Biopharma partnership shifts the investment picture for Biohaven in a way that warranted a lower call.
  • The definitive terms of the Biohaven and SK Biopharma arrangement were not detailed in the downgrade, leaving the deal structure as a key unresolved variable for investors.
  • Downgrades from an institution of RBC's standing tend to prompt reassessment across the broader analyst coverage community.
  • Investors are watching for filings clarifying the deal terms and for additional RBC commentary or responses from competing analysts.

RBC Capital Markets has downgraded Biohaven, pointing to the company's recent deal with SK Biopharma as the catalyst for the call. The move puts Biohaven in focus as the market weighs what the arrangement means for the near-term setup.

The SK Biopharma transaction is what drove the action. RBC's decision to step back on the rating signals that, in the firm's view, the partnership with SK Biopharma shifts the investment picture for Biohaven in a way that warranted a lower call. That thesis will be tested. Analyst downgrades from institutions of RBC's standing tend to prompt reassessment across the broader coverage community, and whether others following Biohaven arrive at the same conclusion on the SK Biopharma deal is the next read on the name.

The definitive terms of the Biohaven and SK Biopharma arrangement have not been detailed in the downgrade, so the structure of the deal remains the variable investors need resolved. Any filing that clarifies those terms is what the tape will want to price. Watch for additional RBC commentary or responses from competing analysts on the arrangement as further detail emerges from either company.

Related reading

About this story

Filed by the newsroom of MarketPR on September 8, 2026. Source: MarketPR newsroom. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Cleveland Fed tool projects October core PCE acceleration to 3.13%

The Federal Reserve Bank of Cleveland's Inflation Nowcasting tool projects that core Personal Consumption Expenditures (PCE) will rise to 3.13% in October, marking a reacceleration after three consecutive months of stability at 3%. This…

Renata Ostrowski2 min read
02Macro

Battle Ground runner Elise Bierer quits district race alone over trans competitor

Elise Bierer, a sophomore at Battle Ground High in Washington state, walked off the starting line of the women's varsity cross country race at the Greater St. Helens League District Meet on Wednesday, ending her season in protest. She was…

Renata Ostrowski2 min read
03Macro

Lockheed Martin Integrates Satellites and Interceptors for Layered Defense

Lockheed Martin is integrating independent capabilities into a layered homeland defense architecture. The system connects satellites, radars, and interceptor systems. The company states that this approach addresses evolving threats by…

Renata Ostrowski2 min read

Frequently asked

Why did RBC Capital Markets downgrade Biohaven?

RBC downgraded Biohaven because of the company's recent deal with SK Biopharma, which in the firm's view shifts Biohaven's investment picture in a way that warranted a lower rating.

What are the terms of the Biohaven and SK Biopharma deal?

The definitive terms of the arrangement have not been detailed in the downgrade, so the structure of the deal remains an unresolved variable for investors.

What should investors watch for next?

Investors should watch for any filing that clarifies the deal terms, as well as additional RBC commentary or responses from competing analysts covering Biohaven.

Could other analysts follow RBC's downgrade?

Downgrades from institutions of RBC's standing tend to prompt reassessment across the broader coverage community, so whether others reach the same conclusion on the SK Biopharma deal is the next read on the name.